These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 38022729)

  • 21. Immune System and Hepatocellular Carcinoma (HCC): New Insights into HCC Progression.
    Kotsari M; Dimopoulou V; Koskinas J; Armakolas A
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.
    Chen Y; Wang X; Deng X; Zhang Y; Liao R; Li Y; Yang H; Chen K
    Front Immunol; 2021; 12():676922. PubMed ID: 34335575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An emerging research: the role of hepatocellular carcinoma-derived exosomal circRNAs in the immune microenvironment.
    Xu HZ; Lin XY; Xu YX; Xue HB; Lin S; Xu TW
    Front Immunol; 2023; 14():1227150. PubMed ID: 37753074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma.
    Maestri M; Pallozzi M; Santopaolo F; Cerrito L; Pompili M; Gasbarrini A; Ponziani FR
    Expert Opin Investig Drugs; 2022 Apr; 31(4):347-360. PubMed ID: 35072571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma.
    Peng Y; Liu C; Li M; Li W; Zhang M; Jiang X; Chang Y; Liu L; Wang F; Zhao Q
    Cancer Cell Int; 2021 Feb; 21(1):98. PubMed ID: 33568167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging Role of Circular RNAs in Hepatocellular Carcinoma Immunotherapy.
    Abaza T; El-Aziz MKA; Daniel KA; Karousi P; Papatsirou M; Fahmy SA; Hamdy NM; Kontos CK; Youness RA
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor suppressor gene mutations correlate with prognosis and immunotherapy benefit in hepatocellular carcinoma.
    Liu Z; Liu L; Guo C; Yu S; Meng L; Zhou X; Han X
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108340. PubMed ID: 34789428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence.
    Zhang S; Yuan L; Danilova L; Mo G; Zhu Q; Deshpande A; Bell ATF; Elisseeff J; Popel AS; Anders RA; Jaffee EM; Yarchoan M; Fertig EJ; Kagohara LT
    Genome Med; 2023 Sep; 15(1):72. PubMed ID: 37723590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
    Oura K; Morishita A; Tani J; Masaki T
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combinatorial targeting of immune checkpoints and epigenetic regulators for hepatocellular carcinoma therapy.
    Akce M; El-Rayes BF; Wajapeyee N
    Oncogene; 2023 Mar; 42(14):1051-1057. PubMed ID: 36854723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma.
    Donne R; Lujambio A
    Hepatology; 2023 May; 77(5):1773-1796. PubMed ID: 35989535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a TMErisk model based on immune infiltration in tumour microenvironment to predict prognosis of immune checkpoint inhibitor treatment in hepatocellular carcinoma.
    Yan ZJ; Yu CT; Chen L; Wang HY
    Brief Bioinform; 2023 Mar; 24(2):. PubMed ID: 36882021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma.
    Pourhamzeh M; Asadian S; Mirzaei H; Minaei A; Shahriari E; Shpichka A; Es HA; Timashev P; Hassan M; Vosough M
    Mol Cell Biochem; 2023 Jan; 478(1):23-37. PubMed ID: 35708866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of immune tolerance mechanisms on the efficacy of immunotherapy in primary and secondary liver cancers.
    Sankar K; Pearson AN; Worlikar T; Perricone MD; Holcomb EA; Mendiratta-Lala M; Xu Z; Bhowmick N; Green MD
    Transl Gastroenterol Hepatol; 2023; 8():29. PubMed ID: 37601739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
    Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G
    Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive characterization of ferroptosis in hepatocellular carcinoma revealing the association with prognosis and tumor immune microenvironment.
    Zhu J; Xu X; Jiang M; Yang F; Mei Y; Zhang X
    Front Oncol; 2023; 13():1145380. PubMed ID: 37051544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
    Jiang J; Huang H; Chen R; Lin Y; Ling Q
    Front Immunol; 2023; 14():1092401. PubMed ID: 36875077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
    Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
    Front Immunol; 2020; 11():1037. PubMed ID: 32547550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma.
    Kou L; Xie X; Chen X; Li B; Li J; Li Y
    Cancer Immunol Immunother; 2023 Dec; 72(12):3953-3969. PubMed ID: 37917364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.